Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age

NCT01156792 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

162

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: FP 100
DRUG: GSK2190915 100
DRUG: GSK2190915 300
DRUG: montelukast
DRUG: placebo
DRUG: FP/SAL 100/50

Sponsor

GlaxoSmithKline